Subscribe to RSS
DOI: 10.1055/s-2002-33275
© Georg Thieme Verlag Stuttgart · New York
Positronen-Emissions-Tomographie mit F-18-Fluor-Deoxyglukose (FDG-PET) in der pädiatrischen Onkologie
Positron emission tomography using F-18-fluorodeoxyglucose (FDG PET) in paediatric oncologyPublication History
Publication Date:
08 August 2002 (online)
Zusammenfassung
Der klinische Wert der Positronen-Emissions-Tomographie mit F-18-Fluor-Deoxyglukose (FDG-PET) wurde für eine Reihe von onkologischen Fragestellungen nachgewiesen. In pädiatrisch-onkologischen Erkrankungen wurde der klinische Nutzen der FDG-PET bisher jedoch noch nicht gezeigt. In dieser Übersicht werden die Publikationen, die sich mit der FDG-PET bei pädiatrischen Tumorentitäten beschäftigen, zusammengefasst. Es gibt erste Studien zu ossären Sarkomen, Hirntumoren und Neuroblastomen sowie zum Vergleich der Ganzkörper-FDG-PET mit der Ganzkörper-Magnetresonanztomographie (MRT). Die wenigen Daten zeigen, dass prospektive, multizentrische Studien, die den Nutzen der FDG-PET in der pädiatrischen Onkologie untersuchen, notwendig sind.
Abstract
The clinical impact of positron emission tomography using F-18-fluorodeoxyglucose (FDG PET) has been proven for a variety of oncological problems. However, the clinical benefit of FDG PET is not yet established in pediatric oncological diseases. In this review, publications concerning FDG PET in pediatric tumor entities are summarized. There are first studies in osseous sarcomas, brain tumors, neuroblastomas, and in the comparison of whole-body FDG PET and whole-body magnetic resonance imaging (MRI). The limited data demonstrate that prospective multicenter studies analysing the benefit of FDG PET in pediatric oncology are necessary.
Schlüsselwörter
FDG-PET - Pädiatrie - Onkologie - Sarkome
Key words
FDG PET - Paediatrics - Oncology - Sarcoma
Literatur
- 1 Borgwardt L, Carstensen H, Schmiegelow K, Hojgaard L. Increased FDG uptake in childhood CNS tumors is associated with tumor malignancy. Clin Positron Imaging. 2000; 3 175
- 2 Daldrup-Link H E, Franzius C, Rummeney E J, Laukamp D, Sciuk J, Jürgens H, Link T M. Whole body MRI for detection of bone marrow metastases in pediatric patients: comparison with skeletal scintigraphy and FDG-PET. Am J Roentgenol. 2001; 177 229-236
- 3 Franzius C, Daldrup-Link H E, Sciuk J, Rummeny E J, Bielack S, Jürgens H, Schober O. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001; 12 479-486
- 4 Franzius C, Daldrup-Link H E, Wagner-Bohn A, Sciuk J, Heindel W L, Jürgens H, Schober O. FDG PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002; 13 157-160
- 5 Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18-FDG-PET compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000; 25 874-881
- 6 Franzius C, Sciuk J, Daldrup-Link H E, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med. 2000; 27 1305-1311
- 7 Hoffman J M, Hanson M W, Friedman H S, Hockenberger B M, Oakes W J, Halperin E C, Coleman R E. FDG-PET in pediatric posterior fossa brain tumors. J Comput Assist Tomogr. 1992; 16 62-68
- 8 Holthoff V A, Herholz K, Berthold F, Widemann B, Schroder R, Neubauer I, Heiss W D. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 1993; 72 1394-1403
- 9 Kaplan A M, Bandy D J, Manwaring K H, Chen K, Lawson M A, Moss S D, Duncan J D, Wodrich D L, Schnur J A, Reiman E M. Functional brain imaging using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J Neurosurg. 1999; 91 797-803
- 10 Kushner B H, Yeung H WD, Larson S M, Kramer K, Chueng N-K V. Extending positron emission tomography scan utility to high-risk euroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Cin Oncol. 2001; 19 3397-3405
- 11 Molenkamp G, Riemann B, Kuwert T, Sträter R, Kurlemann G, Schober O, Jürgens H, Wolff J E. Monitoring tumor activity in low grade glioma of childhood. Klin Padiatr. 1998; 210 239-242
- 12 Nair N, Ali G, Green A A, Lamonica G, Alibazoglu H, Alibazoglu B, Hollinger E F, Ahmed K. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin Positron Imaging. 2000; 3 79-83
- 13 O'Hara S A, Donnelly L F, Coleman R E. Pediatric body applications of FDG PET. Am J Roentgen. 1999; 172 1019-1024
-
14 Kindertumorregister in Mainz. (1980-1984)
- 15 Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar M R, Keppler P, Kotzerke J, Guhlmann A, Delling G, Reske S N. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET. J Nucl Med. 1999; 40 1637-1643
- 16 Shulkin B L, Chang E, Strouse P J, Bloom D A, Hutchinson R J. PET FDG studies of Wilms tumors. J Pediatr Hematol Oncol. 1997; 19 334-338
- 17 Shulkin B L, Hutchinson R J, Castle V P, Yanik G A, Shapiro B, Sisson J C. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996; 199 743-750
- 18 Shulkin B L, Michell D S, Ungar D R, Prakash D, Dole M G, Castle V P, Hernandez R J, Koeppe R A, Hutchinson R J. Neoplasms in a pediatric population: 2-(F-18)-fluoro-2-deoxy-D-glucose PET studies. Radiology. 1995; 194 495-500
- 19 Weinblatt M E, Zanzi I, Belakhlef A, Babchyck B, Kochen J. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med. 1997; 38 888-890
Dr. Christiane Franzius
Klinik und Poliklinik für Nuklearmedizin
Universitätsklinikum Münster
Albert-Schweitzer-Str. 33
48129 Münster
Phone: + 49-25 18 34 73 62
Fax: + 49-25 18 34 73 83
Email: franziu@uni-muenster.de